King Pharmaceuticals Fined For Air Pollution | Chemical & Engineering News
Volume 91 Issue 27 | p. 21 | Concentrates
Issue Date: July 8, 2013

King Pharmaceuticals Fined For Air Pollution

Department: Government & Policy
Keywords: King Pharmaceuticals, Pfizer, UPM Pharmaceuticals, air pollution, emissions, Clean Air Act
[+]Enlarge
King Pharmaceuticals has its headquarters in Bristol, Tenn.
Credit: vhasler
King Pharmaceuticals, Inc. headquarters in Bristol, Tennessee.
 
King Pharmaceuticals has its headquarters in Bristol, Tenn.
Credit: vhasler

King Pharmaceuticals has agreed to pay a $2.2 million fine and take steps to resolve allegations by federal prosecutors that emissions from the drug manufacturer’s Bristol, Tenn., plant violated the Clean Air Act. According to the complaint, King failed to adequately control emissions of methylene chloride and other hazardous air pollutants, violated the terms of its construction permit, and did not obtain the proper operating permit, as required under the Clean Air Act. The penalty should send a strong signal to the pharmaceutical industry that federal antipollution standards will be enforced, says Acting U.S. Assistant Attorney General Robert G. Dreher. On May 29, Baltimore-based UPM Pharmaceuticals announced it had purchased the 500,000-sq-ft Bristol plant from Pfizer, which acquired King in 2010 as a wholly owned subsidiary. Pfizer says the enforcement action began several years before the company bought King and “all underlying issues were corrected before or shortly after the acquisition.”

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment